Biotech RadarJobs updated

COMPANY

aTyr Pharma

HQ: San Diego, CA source · atyrpharma.com ↗

Clinical Phase 3

aTyr Pharma is listed on ClinicalTrials.gov as the lead sponsor of 9 studies; the most recently updated is “Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis” (Phase 3, completed), in Pulmonary Sarcoidosis. From public records Source · Oct 12, 2026

Keywords: immunology interstitial lung disease fibrosis respiratory Facioscapulohumeral Muscular Dystrophy Pulmonary Sarcoidosis Limb Girdle Muscular Dystrophy Limb-Girdle Muscular Dystrophies SARS-CoV-2 (COVID-19) Severe Pneumonia ATYR1940

Location: San Diego, CA · source · Oct 13, 2026

Profile checked Oct 10, 2026

9Trials (company is sponsor)

Timeline

  1. Trial start Phase 2: Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD) source ↗
  2. Trial start Phase 3: Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis source ↗
  3. Trial start Phase 2: Study to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Participants With Severe Pneumonia Related to COVID-19 source ↗
  4. Trial start Phase 1/Phase 2: Study of Intravenous ATYR1923 (Efzofitimod) for Pulmonary Sarcoidosis source ↗
  5. Trial start Phase 1/Phase 2: Study to Evaluate the Long-Term Safety, Tolerability, and Biological Activity of ATYR1940 in Participants With Limb Girdle and Facioscapulohumeral Muscular Dystrophy (FSHD) source ↗
  6. Trial start Phase 1/Phase 2: Evaluate Safety and Biological Activity of ATYR1940 in Participants With Early Onset Facioscapulohumeral Muscular Dystrophy source ↗
  7. Trial start Phase 1/Phase 2: Evaluate Safety and Biological Activity of ATYR1940 in Participants With Limb Girdle Muscular Dystrophy 2B (LGMD2B) and Facioscapulohumeral Muscular Dystrophy (FSHD) source ↗
  8. Trial start Phase 1/Phase 2: Safety, Tolerability, Pharmacokinetics (PK), and Activity of ATYR1940 in Participants With Muscular Dystrophy - Study Extension source ↗
  9. Trial start Phase 1/Phase 2: Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATYR1940 in Adult Participants With Muscular Dystrophy source ↗

Clinical trials (lead sponsor) 9

RecordTitlePhaseStatusStartPrimary completion
NCT05415137Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary SarcoidosisPhase 3CompletedSep 15, 2022Jun 25, 2025 (actual)
NCT05892614Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)Phase 2RecruitingOct 26, 20232026-04 (estimated)
NCT02836418Study to Evaluate the Long-Term Safety, Tolerability, and Biological Activity of ATYR1940 in Participants With Limb Girdle and Facioscapulohumeral Muscular Dystrophy (FSHD)Phase 1/Phase 2CompletedJul 13, 2016Apr 18, 2017 (actual)
NCT02579239Evaluate Safety and Biological Activity of ATYR1940 in Participants With Limb Girdle Muscular Dystrophy 2B (LGMD2B) and Facioscapulohumeral Muscular Dystrophy (FSHD)Phase 1/Phase 2CompletedNov 30, 2015Oct 5, 2016 (actual)
NCT02603562Evaluate Safety and Biological Activity of ATYR1940 in Participants With Early Onset Facioscapulohumeral Muscular DystrophyPhase 1/Phase 2CompletedMar 30, 2016Dec 12, 2016 (actual)
NCT02531217Safety, Tolerability, Pharmacokinetics (PK), and Activity of ATYR1940 in Participants With Muscular Dystrophy - Study ExtensionPhase 1/Phase 2CompletedAug 13, 2015May 26, 2016 (actual)
NCT04412668Study to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Participants With Severe Pneumonia Related to COVID-19Phase 2CompletedJun 4, 2020Oct 23, 2020 (actual)
NCT03824392Study of Intravenous ATYR1923 (Efzofitimod) for Pulmonary SarcoidosisPhase 1/Phase 2CompletedJan 29, 2019Jun 29, 2021 (actual)
NCT02239224Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATYR1940 in Adult Participants With Muscular DystrophyPhase 1/Phase 2CompletedSep 4, 2014Dec 14, 2015 (actual)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Feedback